Clinical Trial Update: Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating inhaled AP-PA02 for safety and tolerability in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Lung Infection

Drugs mentioned

• AP-PA02

Snippet

Sponsor: Armata Pharmaceuticals, Inc. | Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-31